)
)
)
HydroGene Therapeutics
HydroGene has developed a non-viral DNA delivery platform to create accessible gene therapy for all liver diseases. The approach solves the limitations of AAV approaches (cost, toxicity, lack of redosing), while achieving large DNA delivery allows for mutation agnostic correction, addressing the limitations of gene editing approaches.
HydroGene has validated the approach in non-human primate models and are looking for investors to help fund translation into clinical trials. Our focus is on proof of concept studies in rare genetic liver diseases.
Address
CambridgeMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)